Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial
Valentín Ortiz-Maldonado, MDa,e,f ∙ Núria Martínez-Cibrian, MDa,e,f ∙ Leticia Alserawan, BPharmb,e ∙ Marta Español-Rego, BPharmb,e ∙ Sergio Navarro-Velázquez, BScb,e ∙ Nil Albiol, MDa,e,f ∙ et al.
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00328-X/abstract?utm_campaign=update-lanhae&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanhae&_hsenc=p2ANqtz-9ERAc1k4ZivAtyYe7PQ-Ft9Aj10fyfWgQLMGzFdZ5f0_qm61i1yRq-zvcEOcw0F4ouNZrlBXYk9PY7a6aBN_P5DQiWJQ&_hsmi=408878165&utm_content=408392511&utm_source=hs_email
Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial
Esther N Olíva, MDa enoliva@gmail.com ∙ Francesco Cottone, PhDb ∙ Sudhir Unni, PhDc ∙ Anne Correges, MSd ∙ Jes B Hansen, MSe ∙ Xiaocong Li Marston, PhDf ∙ et al.
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00361-8/abstract?utm_campaign=update-lanhae&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanhae&_hsenc=p2ANqtz--9lCrjEwUlFyJdJ2NNPFxVufe1XDr_Q-kAJIBHurJ8u8Q7i4rABw2EweYL4Yy-Wx1GDK2GaeqFnK2s3WQ6NUI2Jte7CQ&_hsmi=408878165&utm_content=408392511&utm_source=hs_email
Global equity in paediatric cancer care
The Lancet Haematology
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00042-6/fulltext?dgcid=hubspot_update_feature_updatealerts_lanhae&utm_campaign=update-lanhae&utm_medium=email&_hsenc=p2ANqtz--H8oTyxujatb_YqEx2bVOj_Fa_hoJ8wq7PKRpknaqlsOCA4jdJkFsxeqY0T4tXYYoqCUbqkMmrspU9ACjlYYjmLH_FGQ&_hsmi=408878165&utm_content=408392511&utm_source=hs_email
Mar 2026
Volume 13Number 3e119-e186
https://www.thelancet.com/journals/lanhae/issue/vol13no3/PIIS2352-3026(26)X
No hay comentarios:
Publicar un comentario